#TYK2i #deucravacitinib #RCT in #SLE LTE of #PAISLEY #RCT PERSISTENT #LLDAS &#DORIS #remission over 3 more yrs post 1 yr RCT BUT ++dropouts #POS0695 #EULAR2026 @RheumNow https://t.co/vtrMYrFmJ9

• https://x.com/Janetbirdope/status/2063550807128023145/photo/1

Who does better in active #RA b/tsDMARD naive? Pt choice TNFi or JAKi OR Pt randomized to TNFI or JAKi? Strangely or not PT choice did better ✅with satisfaction ~maybe expected ✅better retention on chosen #Rx 🤔unexpected another arm in #RCTS?” #EULAR2026 @RheumNow OP0204 https://t.co/7qx5Rqq6a7

• https://x.com/Janetbirdope/status/2063541514844697071/photo/1
• https://x.com/Janetbirdope/status/2063541514844697071/photo/1
• https://x.com/Janetbirdope/status/2063541514844697071/photo/1

Updated SLR on D2T #RA (131 studies): JAKi maintain ACR20 even after 2-3 prior bDMARDs, with UPA outperforming ABA in head-to-head. But evidence on non-pharmacologic strategies in D2T RA remains nearly absent. Clear gap for future trials. @RheumNow #EULAR2026 POS1246

SELECT-Axis 2 trial and Withdrawal of Upadacitinib - Of 734 pts, 194 were in remission at wk104--> UPA w/d & 22% maintained drug-free remission for >48wks. Rest flared, median time to flare: 3.1 mos (89% regained LDA by wk24 w/ restart) #EULAR2026 #axSpA POS1350 https://t.co/7A7CAHxLxX

Risk of Parkinsons? RA patients have 28% lower Parkinson's risk vs general population (HR 0.72); axSpA had HIGHER risk (HR 1.29). Non-TNF biologics in RA reduced PD risk further (HR 0.74). No effect seen in PsA/axSpA. #EULAR2026 Abstr #POS1116 https://t.co/1vZoZGEu5Z

What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission? Data from 194 patients from the SELECT-AXIS2 RCT: ▶️ Remission maintained in 1/4 at48 weeks POS1350 #EULAR2026 @RheumNow https://t.co/Z7nDwMuQux

• https://x.com/Nellziade/status/2063269000612561273/photo/1

#EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE risk: -VTE:Non-inferiority of BARI wasn’t met (in line with JAK profile) -No increase in MACE/Cancer (opposed to Oral-Surveillance: TOFA & =>1 MACE risk) @RheumNow #EULARBest https://t.co/nNwtJ3LbkD

• https://x.com/Yuz6Yusof/status/2063272199788593497/photo/1
• https://x.com/Yuz6Yusof/status/2063272199788593497/photo/1
• https://x.com/Yuz6Yusof/status/2063272199788593497/photo/1
• https://x.com/Yuz6Yusof/status/2063272199788593497/photo/1

https://t.co/LEnQbCB2Ff https://t.co/CtuFVbde6t

• https://x.com/Janetbirdope/status/2063179861397536847/photo/1
• https://x.com/Janetbirdope/status/2063179861397536847/photo/1
• https://x.com/Janetbirdope/status/2063179861397536847/photo/1
• https://x.com/Janetbirdope/status/2063179861397536847/photo/1
• https://twitter.com/eular_ard/status/2062509665024344391

#SLE Rx options Determining #MOA #TYK2 #sig w #deucravacitinib #IFN sig in active #SLE ⬇️ in #anifrolumab #upa #deucra #repeat renal #bx in #obinutuzimab ➡️ Clears B cells #Dapriluzimab & other MOAs ⬇️AntiDNA ⬆️complements #EULARbest @RheumNow #EULAR2026 #POS1364, OP0160,336

#EULAR2026 LB0005 More promising news in #PMR. Phase 3 RCT of Baricitinib + GC Taper in N=46: Part 1: BARI vs PBO 65% vs 17% GC-Free Remission at WK16 2: PBO-BARI improved response 17% to 65% at WK28 3: Lower remission rate in those stopped BARI vs continued at WK44 @RheumNow https://t.co/D77aHcACJE

• https://x.com/Yuz6Yusof/status/2063238362324979886/photo/1
• https://x.com/Yuz6Yusof/status/2063238362324979886/photo/1